Table 5 Distribution and comparison of per patient hospitalisation medical costs (AU$) by post-therapy complications status among cancer patients.

From: Emerging burden of post-cancer therapy complications on unplanned hospitalisation and costs among Australian cancer patients: a retrospective cohort study over 14 years

Therapy and cancer group

Per-patient mean hospital costs in AU$ (SD)

No post-therapy complications

Diagnosed at least post-therapy complications

Difference

Mean costs in AU$ (SD)

Mean costs in AU$ (SD)

Mean difference of costs in AU$ (95% CI)§

p-value

Type of therapy

 Systemic therapy

31,692 (54804)

1,904,443 (5457699)

1,872,751 (1701884 to 2043617)

< 0.001

 Radiation therapy

52,570 (100713)

563,621 (1138623)

511,050 (369222 to 652878.5)

< 0.001

 Systemic therapy and radiotherapy

105,876 (92881)

1,938,516 (4037320)

1,832,640 (1289555 to 2375724)

< 0.001

Cancer group

 Oral

na

1,597,451 (2483528)

-

 

 Bladder

31,446 (70040)

1,670,388 (3973787)

1,638,943 (1263786 to 2014099)

< 0.001

 Pancreatic cancer

na

324,828 (451099)

-

 

 Brain

42,032 (75163)

293,600 (360193)

251,567 (115655 to 387479)

< 0.001

 Cervical cancer

31,360 (62543)

1,396,021 (2241343)

1,364,661 (−184807 to 2914128)

0.084

 Stomach cancer

38,822 (35232)

567,747 (726597)

528,924 (385774 to 672075)

< 0.001

 Esophageal cancer

16,129 (16125)

746,692 (1010441)

730,563 (352396 to 1108730)

< 0.001

 Gastric Cardia

41,754 (60749)

992,009 (2128121)

950,255 (637872 to 1262639)

< 0.001

 Colorectal cancer

27,268 (69874)

544,484 (600855)

517,216 (255136 to 779295)

< 0.001

 Hodgkin lymphoma

17,703 (25205)

1,757,482 (4783267)

1,739,779 (1264646 to 2214913)

< 0.001

 Non-Hodgkin lymphoma

25,142 (54219)

2,311,476 (5534690)

2,286,334 (1965442 to 2607227)

< 0.001

 Multiple myeloma

26,317 (46264)

4,181,140 (7464618)

4,154,824 (35439904 to 4765743)

< 0.001

 Anal canal

34,322 (49013)

1,080,488 (2566112)

1,046,166 (878955.2 to 1213376)

< 0.001

 Liver

34,441 (58711)

661,040 (1359791)

626,600 (373493 to 879707)

< 0.001

 Melanoma of the skin

31,870 (63635)

1,217,749 (3568219)

1,185,879 (655485 to 1716273)

< 0.001

 Pancreas

42,953 (64603)

519,467 (664065)

476,514 (375426 to 577603)

< 0.001

 Lung

42,891 (71657)

591,954 (1093989)

549,063 (480476 to 617650)

< 0.001

 Breast

30,742 (52955)

517,964 (1272254)

487,222 (369801 to 604643)

< 0.001

 Ovary

9465 (8054)

1,234,330 (2082324)

1,224,865 (394806.9 to 2054924)

< 0.001

 Kidney

18,984 (15365)

1,338,223 (2665533)

1,319,239 (456601 to 2181877)

< 0.001

 Thyroid

23,740 (35493)

947,493 (2397821)

923,752 (−91648 to 1939153)

0.075

 III-defined sites

na

na

-

 

 Unspecified malignant neoplasm

40,276 (50704)

672,776 (1317938)

632,500 (527713 to 737287)

< 0.001

 Rectal cancer

54,924 (72478)

690,164 (1037722)

635,240 (291668 to 978812)

< 0.001

 Bone and bone marrow

44,906 (61836)

893,316 (1658943)

848,410 (646756 to 1050063)

< 0.001

 Acute lymphoblastic leukemia

25,949 (40547)

4,868,592 (1100037)

4,842,643 (3914453 to 5770832)

< 0.001

 Others

39,309 (80345)

1,306,230 (3441043)

1,266,921 (1006059 to 1527783)

< 0.001

Overall

33,599 (59464)

1,855,879 (5299788)

1,822,280 (1705155 to 1939405)

< 0.001

  1. §Bootstrap confidence intervals with 1000 replications using generalised linear regression model, p-value = the probability value. na not available, SD standard deviation, LOS length of stay, CI confidence interval.
Back to article page